Elbasvir/grazoprevir

Drug Profile

Elbasvir/grazoprevir

Alternative Names: Elbasvir and grazoprevir; Grazoprevir/elbasvir; MK-5172/MK-8742; MK-5172A; MK-8742/MK-5172; ZEPATIER

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Amides; Antivirals; Benzoxazines; Carbamates; Carboxylic acids; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 24 Jul 2017 Institute Of Cardiology & Internal Diseases, Kazakhstan plans a phase III trial for Hepatitis C in Kazakhstan in October 2017 (NCT03222167)
  • 02 Jun 2017 University of Pennsylvania and Merck initiates enrolment in a phase I/II trial for Hepatitis C in USA (NCT03146741)
  • 24 May 2017 Merck initiates enrolment in a phase II trial for Hepatitis C in France (PO) (NCT02886624)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top